International Journal of Gynecological Cancer最新文献

{"title":"Prognostic value of isolated tumor cells in sentinel lymph nodes in intermediate-risk endometrial cancer: results from an international, multi-institutional study.","authors":"Giuseppe Cucinella, Gabriella Schivardi, Xun Clare Zhou, Mariam M AlHilli, Sumer Wallace, Allan Covens, Christoph Wohlmuth, Glauco Baiocchi, Nedim Tokgozoglu, Francesco Raspagliesi, Alessandro Buda, Vanna Zanagnolo, Ignacio Zapardiel, Nisha Jagasia, Robert Giuntoli, Ariel Glickman, Michele Peiretti, Maximillian Lanner, Enrique Chacon, Julian Di Guilmi, Augusto Pereira, Enora Laas, Ami Fishman, Caroline C Nitschmann, Katherine Kurnit, Kristen Moriarty, Amy Joehlin-Price, Brittany Lees, Louise De Brot, Cagatay Taskiran, Giorgio Bogani, Fabio Landoni, Luis Chiva, Tommaso Grassi, Tommaso Bianchi, Francesco Multinu, Luigi Antonio De Vitis, Alicia Hernandez-Gutierrez, Spyridon Mastroyannis, Khaled Ghoniem, Emilia Palmieri, Vito Chiantera, Shahi Maryam, Angela J Fought, Michaela E McGree, Andrea Mariani, Gretchen Glaser","doi":"10.1016/j.ijgc.2025.101906","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101906","url":null,"abstract":"<p><strong>Objective: </strong>This study assessed oncologic outcomes of patients with intermediate-risk endometrioid endometrial cancer and isolated tumor cells (ITC) (≤0.2 mm or ≤200 cells) in sentinel lymph nodes (SLNs).</p><p><strong>Methods: </strong>Patients with SLN-ITC diagnosed between 2012 and 2019 were identified from 19 centers worldwide, while SLN-negative patients were identified at Mayo Clinic, Rochester between 2014 and 2018. Only patients with endometrioid endometrial cancer and intermediate-risk factors (low-grade endometrioid histology and myometrial invasion ≥50%; high-grade endometrioid histology and myometrial invasion <50%) were included. Oncologic outcomes were evaluated by grouping patients according to prognostic factors: SLN-ITC and lymphovascular space invasion (LVSI). SLN-ITC patients with post-operative observation or vaginal brachytherapy (VB) alone were compared with similar node-negative patients.</p><p><strong>Results: </strong>Of the 166 patients included, those with simultaneous presence of SLN-ITC and LVSI were at higher risk of non-vaginal recurrence (HR 3.73 [95% CI 1.17 to 11.84], p = .01) compared with patients who were node-negative with no LVSI. Among the 122 patients (28 SLN-ITC, 94 node-negative) who underwent post-operative observation or VB alone, 1 isolated vaginal recurrence was documented in a node-negative patient, while non-vaginal recurrence occurred in 3 of 28 (10.7%) SLN-ITC and 7 of 94 (7.4%) node-negative patients. The median follow-up was 2.4 years (interquartile range; 1.8-3.0) among the remaining 25 ITC patients and 2.8 years (interquartile range; 0.8-4.2) among the remaining 87 node-negative patients. There was no difference in non-vaginal recurrence-free survival (SLN-ITC: 87.3% [95% CI 74.7% to 100.0%] vs node-negative: 82.2% [95% CI 69.1% to 97.9%], p = .46) or overall survival (SLN-ITC: 76.4% [95% CI 54.3 to 100.0] vs node-negative: 84.5% [95% CI 75.0 to 95.2], p = .28) between the 2 cohorts.</p><p><strong>Conclusions: </strong>In patients with endometrioid endometrial cancer and intermediate-risk factors (including patients who received chemotherapy/external beam radiotherapy), the combination of SLN-ITC and LVSI was associated with worse prognosis compared with patients with no risk factors or only 1 risk factor. In the sub-group of patients who received post-operative observation or VB alone, SLN-ITC did not worsen prognosis relative to node-negative patients.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101906"},"PeriodicalIF":4.1,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A randomized clinical trial to assess the effectiveness of thermal ablation versus loop electrosurgical excision procedure for cervical cancer risk reduction in women living with HIV in Mozambique.","authors":"Parisa N Fallah, Mila P Salcedo, Edna Nhacule, Yolanda Utui, Marcia M Massinga, Nafissa B Osman, Guilhermina G Tivir, Carla Carrilho, Eliane Monteiro, Ricardina Rangeiro, Andrea Neves, Dercia Changule, Arlete Mariano, Alberto Machaze, Celso E Castiano, Ellen Baker, Jose Jeronimo, Elizabeth Y Chiao, Mark F Munsell, Melissa L Varon, Jessica Milan, Joseph P Thomas, Rebecca Richards-Kortum, Cesaltina Lorenzoni, Edna N Omar Viegas, Philip E Castle, Kathleen M Schmeler","doi":"10.1016/j.ijgc.2025.101905","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101905","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer remains a leading cause of death in low- and middle-income countries. Women living with human immunodeficiency virus (HIV) carry a 6-fold higher risk of cervical cancer than the general population. The effectiveness of thermal ablation versus loop electrosurgical excision procedure (LEEP) in women living with HIV is uncertain, prompting this study.</p><p><strong>Primary objective: </strong>To compare the effectiveness of thermal ablation versus LEEP for the management of abnormal cervical cancer screening results in women living with HIV.</p><p><strong>Study hypothesis: </strong>Thermal ablation is non-inferior to LEEP for treatment of cervical intra-epithelial neoplasia (CIN) 2/3 and high-risk human papillomavirus (hrHPV) infection in women living with HIV.</p><p><strong>Trial design: </strong>This is a prospective randomized clinical trial. Participants undergo screening with primary hrHPV testing. Those with positive hrHPV results undergo visual inspection with acetic acid and a review of genotyping results to determine eligibility for treatment. Those who are hrHPV-positive and positive by visual assessment with acetic acid, or human papillomavirus16/18 positive regardless of visual assessment with acetic acid result, are randomized to thermal ablation or LEEP. Participants undergo follow-up at 4 to 8 weeks, 6 months, and 12 months post-procedure.</p><p><strong>Major inclusion/exclusion criteria: </strong>Participants include 25 to 49-year-old women living with HIV in Mozambique. Exclusion criteria include pregnancy, previous total hysterectomy, history of cervical cancer or prior treatment for CIN, or any condition that would preclude adherence to the study protocol.</p><p><strong>Primary endpoints: </strong>Persistent or recurrent CIN 2/3 (or worse diagnosis) and hrHPV infection at 12 months after initial treatment.</p><p><strong>Sample size: </strong>To meet our primary objectives and to achieve a power of 0.8 (α = 0.025), we will need to randomize 126 participants with CIN 2/3, 63 to thermal ablation, and 63 to LEEP. We estimate that this will require screening a total of 4844 women living with HIV.</p><p><strong>Estimated dates for completing accrual and presenting results: </strong>We anticipate that study accrual will be completed in 3 years (2027), with an additional 18 months to complete all follow-up visits and data analysis. We anticipate presenting results in 2029.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov #NCT06326294.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101905"},"PeriodicalIF":4.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144119651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Declaration on cervical cancer elimination: literature review and perspectives from early-career clinicians.","authors":"Joanna Kacperczyk-Bartnik, Houssein El Hajj, Icó Tóth, Nicolò Bizzarri, Richard Tóth, Zoia Razumova, Tibor Andrea Zwimpfer, Nadja Taumberger, Esra Bilir, Aleksandra Strojna, Martina Aida Angeles, Khayal Gasimli, Tanja Nikolova, Paweł Bartnik, Andrej Cokan, Sezin Yuce Sari, Ilker Kahramanoglu, Giuseppe Caruso, Elmar A Joura, Maria Kyrgiou, Vesna Kesic, Anna Fagotti, Marc Arbyn, Murat Gultekin","doi":"10.1016/j.ijgc.2025.101902","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101902","url":null,"abstract":"<p><p>Despite effective prevention methods, cervical cancer remains one of the most incident malignancies globally. This literature review and perspectives from early-career clinicians aim to propose actionable recommendations to reduce the global burden of cervical cancer. The authors, representing the early-career clinicians and researchers, patient representatives, epidemiologists, and gynecologic oncology experts, identified 5 key pillars for cervical cancer elimination based on literature reviews and interdisciplinary discussion: (1) raising awareness of human papillomavirus (HPV) and cervical cancer; (2) ensuring evidence-based HPV communication; (3) fostering collaboration with other specialties and organizations; (4) increasing HPV vaccination rates; and (5) improving cervical cancer screening. Achieving the World Health Organization's cervical cancer elimination target by 2030 requires a comprehensive, multi-faceted approach. Our recommendations emphasize the need for targeted awareness campaigns, evidence-based communication, collaboration with various stakeholders, promotion of best practices, and keeping evidence of innovative interventions up-to-date, with intensified efforts in low- and middle-income countries where the burden is the greatest.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101902"},"PeriodicalIF":4.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144173804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An ambispective, real-world multi-center study of DOstarlimab in patients with Recurrent or Advanced DNA mismatch repair deficient/microsatellite instability-high endometrial cancer (GEICO 120-R/DORA study).","authors":"Alejandro Gallego, Ainhoa Madariaga, Purificación Estévez-García, Facundo Albertí, Anna Carbó, Isabel Palacio, Cristina Churruca, Fernando Gálvez, María Eugenia Ortega, Paola Murata, Aránzazu Manzano, María Masvidal, Cristina Martín-Lorente, Blanca Hernando, Inmaculada Lozano, Juan F Cueva, David García-Illescas, Ester Gost, Marta Mendiola, Andrés Redondo","doi":"10.1016/j.ijgc.2025.101903","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101903","url":null,"abstract":"<p><strong>Objective: </strong>Patients with advanced or recurrent endometrial cancer who experience progression following platinum-based chemotherapy have limited treatment options. The phase I GARNET trial showed the high efficacy of dostarlimab in treating mismatch repair deficient (dMMR) and/or microsatellite instability-high (MSI-H) endometrial cancer.</p><p><strong>Methods: </strong>DORA is a multi-center, ambispective, observational real-world study evaluating the efficacy and safety of dostarlimab. The study included patients with dMMR/MSI-H endometrial cancer who had experienced tumor progression on or after a platinum-based treatment and had received at least 1 cycle of dostarlimab within the Spanish Expanded Access Program. The primary endpoints were objective response rate and duration of response.</p><p><strong>Results: </strong>A total of 129 patients from 57 of the Spanish Research Group for Gynaecological Cancer (GEICO) affiliated hospitals were enrolled, with 125 evaluable for radiological response. The median duration of dostarlimab administration was 8.8 months (interquartile range; 13.2), and 73 patients (57%) remained on therapy at the data cutoff. With a median follow-up of 11.6 months (range; 0.8-30.1), the objective response rate was 53.6% (95% CI 44.4 to 62.5). Complete response was observed in 27 patients (21.6%), and partial response in 40 (32%), with a median time to response of 2.9 months (95% CI 2.6 to 3.6). The median duration of response was not reached. The probability of maintaining the response at 12 and 24 months was 84.98% (95% CI 70.8 to 92.5) and 73.39% (95% CI 50.5 to 86.9), respectively. Treatment was discontinued due to toxicity in 4.7% of patients.</p><p><strong>Conclusions: </strong>Dostarlimab monotherapy in dMMR/MSI-H endometrial cancer patients shows similar efficacy in real-world practice to that observed in the GARNET trial.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101903"},"PeriodicalIF":4.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The art of prevention: merging creativity and medicine to transform cervical cancer awareness.","authors":"Gil Zeevi, Ram Eitan","doi":"10.1016/j.ijgc.2025.101909","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101909","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101909"},"PeriodicalIF":4.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clear cell carcinoma of the cervix positive for HPV16.","authors":"Christine G T Nguyen, Benjamin F Smith, Athena Chen, Jenna Emerson","doi":"10.1016/j.ijgc.2025.101907","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101907","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101907"},"PeriodicalIF":4.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144110687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oncologic outcomes of sentinel lymph node mapping in patients with high-intermediate- and high-risk endometrial cancer: a systematic review and meta-analysis.","authors":"Jacqueline Nunes de Menezes, Daniel Mioto Mataruco, Raíssa Êmily Andrade Souza, Gabriela Branquinho Guerra, Beatriz Pâmella Costa Bomfim, Isadora da Silveira, Ana Thereza da Cunha Uchoa, Glauco Baiocchi, Pedro T Ramirez","doi":"10.1016/j.ijgc.2025.101901","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101901","url":null,"abstract":"<p><strong>Objective: </strong>Sentinel lymph node (SLN) mapping has not been widely adapted in the setting of high-intermediate and high-risk endometrial cancer. The goal of this study was to determine oncologic outcomes in this high-intermediate or high-risk population undergoing SLN mapping compared with systematic pelvic ± para-aortic lymphadenectomy.</p><p><strong>Methods: </strong>In accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines, MEDLINE, Embase, and Cochrane databases were searched for trials comparing SLN with lymphadenectomy for patients with high- or high-intermediate-risk endometrial cancer. Studies were excluded if they lacked a control group, involved overlapping populations, were only available as abstracts, or were not in English. The main outcomes were overall survival, disease-free survival, recurrence, and adjuvant therapy rates. A pre-specified sub-group analysis was carried out that included high-risk patients, high-intermediate-risk patients, and only propensity score-matched studies. Statistical analysis was performed using RStudio Version 4.4.0. Heterogeneity was assessed using I² statistics.</p><p><strong>Results: </strong>A total of 10 observational studies (2 with population data from the National Center for Biotechnology Information - NCBI and the Surveillance, Epidemiology and End Results - SEER databases) were included, evaluating a total of 6127 patients. There were no randomized control trials. There were no differences regarding overall survival (HR 0.82, 95% CI 0.60 to 1.11, p = .19, I² = 36%) or disease-free survival (HR 0.85, 95% CI 0.67 to 1.08, p = .19, I² = 0%) between SLN mapping and lymphadenectomy. Recurrence rates (OR 0.79, 95% CI 0.58 to 1.06, p = .12, I² = 0%) and adjuvant therapy (OR 1.39, 95% CI 0.78 to 2.48, p = .26, I² = 85%) were also similar between the groups. In a sub-group analysis including only the high-risk population, a statistically significant difference in overall survival favored SLN mapping compared with the lymphadenectomy (OR 0.62, 95% CI 0.44 to 0.89, p < .01, I² = 0%). Similarly, the analysis of propensity score-matched studies showed better overall survival in the SLN cohort (OR 0.61, 95% CI 0.43 to 0.87, p < .01, I² = 0%).</p><p><strong>Conclusions: </strong>SLN mapping is associated with similar oncologic outcomes to lymphadenectomy in patients with high-intermediate and high-risk endometrial cancer. Routine lymphadenectomy should no longer be considered a standard of care.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101901"},"PeriodicalIF":4.1,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144215766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The histopathologic and molecular findings of neurotrophic tyrosine kinase receptor-rearranged uterine sarcoma.","authors":"Whitney Rich, Natalie Banet","doi":"10.1016/j.ijgc.2025.101898","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101898","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101898"},"PeriodicalIF":4.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093390","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When Impact Multiplies: Defining Trials and Insights from the 2025 Society of Gynecologic Oncology Annual Meeting.","authors":"Mariana Carvalho Gouveia, Jéssica Monteiro Vasconcellos, Letícia Vecchi Leis, Mariana Scaranti","doi":"10.1016/j.ijgc.2025.101895","DOIUrl":"https://doi.org/10.1016/j.ijgc.2025.101895","url":null,"abstract":"<p><p>\"When Impact Multiplies: Defining Trials and Insights From the 2025 Society of Gynecologic Oncology Annual Meeting\" features the most significant and potentially practice-changing research presented at the Annual Meeting on Women's Cancer. Held in Seattle, WA from March 14 to 17, 2025, the Society of Gynecologic Oncology Annual Meeting remains one of the premier conferences for professionals dedicated to advancing gynecologic cancer care. The scientific program covered a broad spectrum of topics across gynecologic oncology, highlighting the latest advancements in research, clinical practice, and patient-centered care. From this comprehensive program, we selected 14 studies considered to be highly impactful.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 7","pages":"101895"},"PeriodicalIF":4.1,"publicationDate":"2025-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144093556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Duplication of inferior vena cava: a case of retroperitoneal secondary cytoreductive surgery.","authors":"Giulio Bonaldo, Vicente Bebia","doi":"10.1136/ijgc-2024-005902","DOIUrl":"https://doi.org/10.1136/ijgc-2024-005902","url":null,"abstract":"","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":" ","pages":"101890"},"PeriodicalIF":4.1,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143994496","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}